Author:
Lello Stefano,Scambia Giovanni,Capozzi Anna
Abstract
SommarioL’osteoporosi postmenopausale è un processo per il quale il tessuto osseo sviluppa una fragilità risultando più suscettibile alle fratture anche per traumi che solitamente non comporterebbero tali eventi. La carenza estrogenica è un punto fondamentale nella patogenesi dell’osteoporosi. La TOS rappresenta un trattamento di scelta nella prevenzione della osteoporosi e delle fratture correlate, soprattutto nei primi anni di postmenopausa.
Publisher
Springer Science and Business Media LLC
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference22 articles.
1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785–795
2. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel (2017) The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 24(7):728–753
3. Cauley JA, Robbins J, Chen Z (2003) Women’s Health Initiative Investigators et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290:1729–1738
4. Anderson GL, Limacher M, Assaf AR et al. (for the Women’s Health Initiative Steering Committee) (2004) Effects of conjugated estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712
5. Cagnacci A, Gambacciani M, Gallo M, Lello S (for the Executive Committee of The Italian Society of Menopause (SIM) and The Italian Society of Gynecology of Third Age (SIGiTE)) (2019) Recommendations on menopausal hormone replacement therapy. Minerva Ginecol 71(6):395–403